Your browser doesn't support javascript.
loading
Early target attainment of azithromycin therapy in children with lower respiratory tract infections.
Liu, Shuping; Zheng, Yi; Wu, Xirong; Xu, Baoping; Liu, Xiuyun; Feng, Guoshuang; Sun, Lin; Shen, Chen; Li, Jieqiong; Tang, Bohao; Jacqz-Aigrain, Evelyne; Zhao, Wei; Shen, Adong.
Affiliation
  • Liu S; Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institut
  • Zheng Y; Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
  • Wu X; China National Clinical Research Center for Respiratory Diseases, Respiratory Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Xu B; China National Clinical Research Center for Respiratory Diseases, Respiratory Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Liu X; China National Clinical Research Center for Respiratory Diseases, Respiratory Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Feng G; Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Sun L; Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institut
  • Shen C; Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institut
  • Li J; Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institut
  • Tang B; Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
  • Jacqz-Aigrain E; Department of Pediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, APHP, Paris, France.
  • Zhao W; Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
  • Shen A; Department of Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China.
J Antimicrob Chemother ; 73(10): 2846-2850, 2018 10 01.
Article in En | MEDLINE | ID: mdl-30060209
ABSTRACT

Objectives:

Early target attainment is the key factor influencing the outcome of antimicrobial therapy. The objective of the present study was to evaluate the relationship between azithromycin concentrations during the first 24-48 h of therapy and the clinical outcome in order to optimize antimicrobial therapy.

Methods:

All children with lower respiratory tract infections receiving intravenous azithromycin monotherapy were included. The relationship between azithromycin trough concentrations during the first 24-48 h and the effectiveness and safety was explored.

Results:

Data from 44 children [mean (SD) age = 5.25 (3.72) years] were available for final analysis. Children with trough concentrations >0.25 mg/L (n = 8) had a more significant improvement in antibacterial efficacy in terms of decreased C-reactive protein (P = 0.006) and the percentage of neutrophils (P = 0.043) compared with children with trough concentrations ≤0.25 mg/L (n = 36). No drug-related adverse events were shown to have a causal association with azithromycin therapy.

Conclusions:

Our study showed the clinical benefits of early target attainment of azithromycin therapy. A target trough concentration of 0.25 mg/L in the first 24-48 h of hospitalization was required to ensure better antibacterial efficacy.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Respiratory Tract Infections / Azithromycin / Anti-Bacterial Agents Limits: Child / Child, preschool / Humans Language: En Year: 2018 Type: Article

Full text: 1 Database: MEDLINE Main subject: Respiratory Tract Infections / Azithromycin / Anti-Bacterial Agents Limits: Child / Child, preschool / Humans Language: En Year: 2018 Type: Article